Effects of chess-based cognitive remediation training as therapy add-on in alcohol and tobacco use disorders: protocol of a randomised, controlled clinical fMRI trial.
Adult psychiatry
Magnetic resonance imaging
Substance misuse
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
06 09 2022
06 09 2022
Historique:
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
26
1
2023
Statut:
epublish
Résumé
Alcohol and tobacco use disorders (AUD, TUD) are frequent, both worldwide and in the German population, and cognitive impairments are known to facilitate instances of relapse. Cognitive training has been proposed for enhancing cognitive functioning and possibly improving treatment outcome in mental disorders. However, these effects and underlying neurobiological mechanisms are not yet fully understood regarding AUD and TUD. Examining the effect of chess-based cognitive remediation training (CB-CRT) on neurobiological, neuropsychological and psychosocial aspects as well as treatment outcomes will provide insights into mechanisms underlying relapse and abstinence and might help to improve health behaviour in affected individuals if used as therapy add-on. N=96 individuals with either AUD (N=48) or TUD (N=48) between 18 and 65 years of age will participate in a randomised, controlled clinical functional MRI (fMRI) trial. Two control groups will receive treatment as usual, that is, AUD treatment in a clinic, TUD outpatient treatment. Two therapy add-on groups will receive a 6-week CB-CRT as a therapy add-on. FMRI tasks, neurocognitive tests will be administered before and afterwards. All individuals will be followed up on monthly for 3 months. Endpoints include alterations in neural activation and neuropsychological task performance, psychosocial functioning, and relapse or substance intake. Regarding fMRI analyses, a general linear model will be applied, and t-tests, full factorial models and regression analyses will be conducted on the second level. Behavioural and psychometric data will be analysed using t-tests, regression analyses, repeated measures and one-way analyses of variance. This study has been approved by the ethics committee of the medical faculty Mannheim of the University of Heidelberg (2017-647N-MA). The findings of this study will be presented at conferences and published in peer-reviewed journals. The study was registered in the Clinical Trials Register (trial identifier: NCT04057534 at clinicaltrials.gov).
Sections du résumé
BACKGROUND
Alcohol and tobacco use disorders (AUD, TUD) are frequent, both worldwide and in the German population, and cognitive impairments are known to facilitate instances of relapse. Cognitive training has been proposed for enhancing cognitive functioning and possibly improving treatment outcome in mental disorders. However, these effects and underlying neurobiological mechanisms are not yet fully understood regarding AUD and TUD. Examining the effect of chess-based cognitive remediation training (CB-CRT) on neurobiological, neuropsychological and psychosocial aspects as well as treatment outcomes will provide insights into mechanisms underlying relapse and abstinence and might help to improve health behaviour in affected individuals if used as therapy add-on.
METHODS AND ANALYSIS
N=96 individuals with either AUD (N=48) or TUD (N=48) between 18 and 65 years of age will participate in a randomised, controlled clinical functional MRI (fMRI) trial. Two control groups will receive treatment as usual, that is, AUD treatment in a clinic, TUD outpatient treatment. Two therapy add-on groups will receive a 6-week CB-CRT as a therapy add-on. FMRI tasks, neurocognitive tests will be administered before and afterwards. All individuals will be followed up on monthly for 3 months. Endpoints include alterations in neural activation and neuropsychological task performance, psychosocial functioning, and relapse or substance intake. Regarding fMRI analyses, a general linear model will be applied, and t-tests, full factorial models and regression analyses will be conducted on the second level. Behavioural and psychometric data will be analysed using t-tests, regression analyses, repeated measures and one-way analyses of variance.
ETHICS AND DISSEMINATION
This study has been approved by the ethics committee of the medical faculty Mannheim of the University of Heidelberg (2017-647N-MA). The findings of this study will be presented at conferences and published in peer-reviewed journals.
TRIAL REGISTRATION
The study was registered in the Clinical Trials Register (trial identifier: NCT04057534 at clinicaltrials.gov).
Identifiants
pubmed: 36691127
pii: bmjopen-2021-057707
doi: 10.1136/bmjopen-2021-057707
pmc: PMC9454048
doi:
Banques de données
ClinicalTrials.gov
['NCT04057534']
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e057707Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Neuropsychopharmacology. 2020 Apr;45(5):720-735
pubmed: 31905368
Nervenarzt. 2007 Jun;78(6):651-6
pubmed: 16832698
Appl Neuropsychol Adult. 2013 Oct-Dec;20(4):277-291
pubmed: 23445503
Dtsch Arztebl Int. 2019 Sep 2;116(35-36):577-584
pubmed: 31587705
Front Psychol. 2021 Aug 13;12:730165
pubmed: 34489833
Med Clin North Am. 1992 Mar;76(2):305-31
pubmed: 1548964
J Dual Diagn. 2016;12(1):90-106
pubmed: 26828702
Addict Behav. 2008 Oct;33(10):1276-81
pubmed: 18602219
Alcohol Clin Exp Res. 1995 Jun;19(3):600-6
pubmed: 7573780
Nicotine Tob Res. 2008 Nov;10(11):1633-43
pubmed: 18988076
Tob Control. 2006 Dec;15(6):464-71
pubmed: 17130376
Neuropsychology. 1998 Jul;12(3):426-45
pubmed: 9673998
Addict Behav. 2008 Dec;33(12):1516-20
pubmed: 18706769
Pers Individ Dif. 2017 Oct 1;116:73-85
pubmed: 28974825
Psychol Health. 2017 Aug;32(8):1018-1036
pubmed: 28553727
J Abnorm Psychol. 1982 Jun;91(3):199-209
pubmed: 7096790
Aust N Z J Psychiatry. 2007 Dec;41(12):957-68
pubmed: 17999268
Pharmacoeconomics. 2007;25(7):605-18
pubmed: 17610340
Alcohol Clin Exp Res. 2010 May;34(5):771-6
pubmed: 20201927
Alcohol Clin Exp Res. 2019 Jan;43(1):135-146
pubmed: 30462837
Eur Arch Psychiatry Clin Neurosci. 2009 Nov;259 Suppl 2:S183-7
pubmed: 19876677
Psychopharmacology (Berl). 2010 Sep;211(4):377-87
pubmed: 20582399
Science. 2016 Jun 17;352(6292):1468-71
pubmed: 27313048
Eur J Neurosci. 2019 Aug;50(3):2513-2525
pubmed: 29787620
JAMA. 2006 May 3;295(17):2003-17
pubmed: 16670409
J Pers Soc Psychol. 1988 Jun;54(6):1063-70
pubmed: 3397865
Nat Neurosci. 2012 Jun;15(6):920-5
pubmed: 22544311
J Int Neuropsychol Soc. 2014 Jul;20(6):620-9
pubmed: 24960301
Addiction. 2006 Feb;101(2):212-22
pubmed: 16445550
Front Psychiatry. 2021 Jul 09;12:649737
pubmed: 34305668
Psychol Med. 2000 Mar;30(2):455-62
pubmed: 10824665
J Stud Alcohol. 2001 Mar;62(2):211-20
pubmed: 11327187
J Health Soc Behav. 1983 Dec;24(4):385-96
pubmed: 6668417
J Clin Exp Neuropsychol. 2002 Aug;24(5):586-604
pubmed: 12187443
Front Psychol. 2015 Sep 01;6:1259
pubmed: 26388797
Clin Psychol Psychother. 2013 Nov-Dec;20(6):494-500
pubmed: 22589026
Neuropsychobiology. 2014;70(2):122-31
pubmed: 25359492
Drug Intell Clin Pharm. 1982 Feb;16(2):145-53
pubmed: 7075465
J Pers Assess. 1985 Feb;49(1):71-5
pubmed: 16367493
Addiction. 2018 Oct;113(10):1905-1926
pubmed: 29749059
Br J Addict. 1991 Nov;86(11):1467-76
pubmed: 1777741
Psychol Psychother. 2016 Mar;89(1):1-14
pubmed: 26208120
Addiction. 2000 Aug;95 Suppl 2:S189-210
pubmed: 11002914
Cochrane Database Syst Rev. 2017 Mar 31;3:CD001007
pubmed: 28361497
Curr Opin Psychiatry. 2015 Nov;28(6):468-72
pubmed: 26382156
Schizophr Res. 2009 Jan;107(1):112-3
pubmed: 18995990
Learn Behav. 2017 Dec;45(4):414-421
pubmed: 28646322
Nicotine Tob Res. 2011 Jul;13(7):548-55
pubmed: 21454912
Nervenarzt. 2004 Sep;75(9):888-95
pubmed: 15378249
Br J Addict. 1991 Sep;86(9):1119-27
pubmed: 1932883
J Int Neuropsychol Soc. 2004 May;10(3):392-400
pubmed: 15147597
Neuropsychology. 2019 Sep;33(6):822-841
pubmed: 31448949
Neuropsychol Rev. 2013 Mar;23(1):27-47
pubmed: 23412885
Addict Biol. 2011 Jan;16(1):166-75
pubmed: 20331560
J Clin Epidemiol. 2015 May;68(5):551-62
pubmed: 25499982
NPJ Sci Learn. 2021 Jun 8;6(1):13
pubmed: 34103531
Cognition. 1994 Apr-Jun;50(1-3):7-15
pubmed: 8039375
Nat Neurosci. 2005 Nov;8(11):1458-63
pubmed: 16251988
Front Psychiatry. 2014 Jul 16;5:78
pubmed: 25076914
Neuroimage. 2013 Dec;83:991-1001
pubmed: 23899722
Biol Psychiatry. 2011 Jun 1;69(11):1060-6
pubmed: 21292243
Addict Behav. 2018 Oct;85:51-63
pubmed: 29852356
Br J Addict. 1989 Nov;84(11):1353-7
pubmed: 2597811
Schizophr Bull. 2011 Sep;37 Suppl 2:S80-90
pubmed: 21860051
Transl Psychiatry. 2013 Dec 17;3:e337
pubmed: 24346135
Neuropsychol Rev. 2007 Sep;17(3):337-45
pubmed: 17680368
Addiction. 2004 Apr;99(4):461-71
pubmed: 15049746
Addiction. 2010 Dec;105(12):2120-7
pubmed: 20854334
Alcohol Clin Exp Res. 2015 Feb;39(2):333-42
pubmed: 25684052
Eur Addict Res. 2005;11(1):50-6
pubmed: 15608472
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
J Clin Psychol. 1995 Nov;51(6):768-74
pubmed: 8778124
Arch Clin Neuropsychol. 2004 Mar;19(2):203-14
pubmed: 15010086
Psychol Sci. 2011 Apr;22(4):498-506
pubmed: 21378368
Addict Biol. 2014 May;19(3):402-14
pubmed: 24147643
Rev Psiquiatr Salud Ment. 2016 Jan-Mar;9(1):13-21
pubmed: 25911280
Front Psychol. 2013 Sep 30;4:665
pubmed: 24137138
J Atten Disord. 2019 Aug;23(10):1119-1125
pubmed: 27138328
Addict Biol. 2018 Jan;23(1):379-393
pubmed: 28111829
Curr Psychiatry Rep. 2011 Oct;13(5):398-405
pubmed: 21792580